ARTICLE | Company News
Genelabs, Watson deal
November 20, 2000 8:00 AM UTC
WPI obtained an exclusive license to market in North America GNLB's Aslera prasterone ( GL701) synthetic dehydroepiandrosterone (DHEA) to treat systemic lupus erythematosus (SLE), an NDA for which is...